A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

Abstract

In patients undergoing primary PCI, a <i>CYP2C19</i> genotype-guided strategy for selection of oral P2Y₁₂ inhibitor therapy was noninferior to standard treatment with ticagrelor or prasugrel at 12 months with respect to thrombotic events and resulted in a lower incidence of bleeding. (Funded by the Netherlands Organization for Health Research and Development; POPular Genetics ClinicalTrials.gov number, NCT01761786; Netherlands Trial Register number, NL2872.).